NY approval of ColonSentry opens door for GeneNews

Last week’s approval by New York State of GeneNews’ (TSX:GEN) ColonSentry molecular diagnostic test to determine a person’s risk of having colorectal cancer opens the door to the entire U.S. market and other jurisdictions around the world for the simple blood test. “Our lead product has now been approved by the most stringent level of [...]

SQI Diagnostics nears big diagnostic contract

SQI Diagnostics (TSX-V:SQD), a maker of in vitro diagnostic (IVD) tests and automated analyzers to process the tests, expects to announce a major diagnostic tools and services customer during the first half of this year to drive near-term revenue. “By successfully achieving our operational milestones, we expect to exit the fourth quarter of 2013 on [...]

In Conversation with Matt Dolan

As a senior research analyst focused on medical technology: (devices and diagnostics) with ROTH Capital Partners, Matt Dolan’s investment views have been cited by a “Who’s Who” of publications on Wall Street. Prior to joining Roth in 2003, Mr. Dolan, a graduate of Northwestern University, formed a trading group at the Chicago Board of Trade [...]

enGene initiates $20 million financing to advance lead product

Closely held enGene of Vancouver is working on a financing of up to $20 million with venture capital funds to conduct the first two phases of human clinical trials of its intestinal immunotherapy platform to treat ulcerative colitis, a major subtype of Inflammatory Bowel Disease (IBD). “We have built significant momentum for the financing in [...]

Alitair builds value without outside investors

Dr. William W. Howard likes to say there’s a lesson to be learned in how closely held Alitair Pharmaceuticals has spent the first couple years of its existence developing a portfolio of respiratory therapeutics and a drug safety technology: make some money first and then go out and get investors. “We’ve been able to develop [...]

Novadaq partnering strategy hits marketing milestone

Novadaq Technologies (TSX:NDQ), a maker of real-time fluorescence imaging products for the operating room, reached a significant milestone earlier this month when it named MAQUET Cardiovascular as the exclusive distributor of its CO2 Heart Laser system in the U.S. “We have now completed our strategic agenda of partnering each one of our first four surgical [...]

Cynapsus readies first human data of sublingual strip for PD

Cynapsus Therapeutics (TSX-V:CTH) is set to release human proof-of-concept data of its sublingual thin film-strip as a treatment for motor fluctuations, or episodes of immobility, in patients with Parkinson’s disease. “This will represent an important de-risking event for the project,” CEO Anthony Giovinazzo says in an exclusive interview with BioTuesdays.com, referring to the company’s APL-130277 [...]

Season’s Greetings (and JPM)

Dear Readers, Wow!  What an interesting year 2011 turned out to be. The BioTuesdays.com team – Len, Maria, Jen, Suh, Shelly, Greg and I – would like to wish you all a safe and happy holiday season.  We are taking a short break to spend time with family and friends. But, we will be back [...]

Northwest Biotherapeutics nearing inflection point

After 15 years of research and clinical testing, Northwest Biotherapeutics (OTCBB:NWBO) is nearing an inflection point in its development of an immunotherapeutic cancer vaccine. “We are entering the home stretch in testing our lead program for the most lethal form of brain cancer, which should reach its primary endpoint in the neighborhood of 18 months,” [...]

BrainStorm readies ALS stem cell testing in U.S.

An experimental treatment developed by BrainStorm Cell Therapeutics (OTCBB:BCLI) that uses a patient’s own stem cells to treat amyotrophic lateral sclerosis (ALS) is expected to begin human clinical trials in the U.S. during 2012. Since ALS is a devastating disease that has limited treatment options, “our personalized therapy has the potential to offer new hope [...]

« Previous Page — Next Page »